

Linda H Ficociello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8867322/publications.pdf>

Version: 2024-02-01

37
papers

2,893
citations

430442

18
h-index

433756

31
g-index

41
all docs

41
docs citations

41
times ranked

3046
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Performance of High-Flux Dialyzers in Patients With Hypoalbuminemia. <i>ASAIO Journal</i> , 2022, 68, 96-102.	0.9	1
2	Antibody Response to the Coronavirus Disease 2019 Ad26.COVS Vaccine Among Maintenance Dialysis Patients. <i>Kidney Medicine</i> , 2022, 4, 100409.	1.0	1
3	Switching from high-flux dialysis to hemodiafiltration: Cost consequences for patients, providers, and payers. <i>Seminars in Dialysis</i> , 2022, , .	0.7	1
4	Global real-world data on hemodiafiltration: An opportunity to complement clinical trial evidence. <i>Seminars in Dialysis</i> , 2022, 35, 440-445.	0.7	3
5	Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort. <i>International Journal of Nephrology and Renovascular Disease</i> , 2022, Volume 15, 139-149.	0.8	0
6	Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1720-1722.	2.2	18
7	Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 11-21.	0.8	26
8	Meeting the Demand for Renal Replacement Therapy during the COVID-19 Pandemic: A Manufacturer's Perspective. <i>Kidney360</i> , 2021, 2, 350-354.	0.9	7
9	Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study. <i>International Journal of Nephrology and Renovascular Disease</i> , 2021, Volume 14, 475-486.	0.8	1
10	Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. <i>Kidney Medicine</i> , 2020, 2, 307-316.	1.0	9
11	Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients. <i>Kidney360</i> , 2020, 1, 263-272.	0.9	3
12	FC024REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
13	Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. <i>BMC Nephrology</i> , 2019, 20, 396.	0.8	10
14	One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis. , 2019, 29, 428-437.		23
15	<p>Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide<p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 1-8.	0.8	18
16	Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide. <i>American Journal of Nephrology</i> , 2018, 47, 153-161.	1.4	20
17	Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. <i>Clinical Nephrology</i> , 2017, 88, 59-67.	0.4	29
18	MP575SERUM PHOSPHORUS AND PHOSPHATE BINDER PILL BURDEN IN DIABETIC HEMODIALYSIS PATIENTS SWITCHED TO SUCROFERRIC OXYHYDROXIDE AS PART OF ROUTINE CARE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i532-i532.	0.4	0

#	ARTICLE	IF	CITATIONS
19	A Comparison of Clinical Parameters and Outcomes over 1 Year in Home Hemodialysis Patients Using 2008K@home or NxStage System One. <i>ASAIO Journal</i> , 2016, 62, 182-189.	0.9	3
20	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1136-1144.	2.2	41
21	Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes. <i>Kidney International</i> , 2013, 83, 1177-1184.	2.6	36
22	Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 516-524.	3.0	307
23	Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. <i>PLoS ONE</i> , 2012, 7, e35655.	1.1	46
24	Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl- β -D-glucosaminidase. <i>Kidney International</i> , 2011, 79, 464-470.	2.6	202
25	A test for the relationship between a time-varying marker and both recovery and progression with missing data. <i>Statistics in Medicine</i> , 2011, 30, 718-724.	0.8	3
26	A Score Test for Association of a Longitudinal Marker and an Event with Missing Data. <i>Biometrics</i> , 2010, 66, 726-732.	0.8	7
27	In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. <i>Kidney International</i> , 2010, 77, 57-64.	2.6	231
28	High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1337-1343.	4.3	191
29	Serum Concentrations of Markers of TNF \pm and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 62-70.	2.2	124
30	Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and Microalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2065-2074.	3.0	136
31	Between hyperfiltration and impairment: Demystifying early renal functional changes in diabetic nephropathy. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, S46-S53.	1.1	34
32	High-Normal Serum Uric Acid Is Associated with Impaired Glomerular Filtration Rate in Nonproteinuric Patients with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 706-713.	2.2	130
33	Association of Urinary Inflammatory Markers and Renal Decline in Microalbuminuric Type 1 Diabetics. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 789-797.	3.0	132
34	Determinants of Progression from Microalbuminuria to Proteinuria in Patients Who Have Type 1 Diabetes and Are Treated with Angiotensin-Converting Enzyme Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 461-469.	2.2	49
35	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1353-1361.	3.0	325
36	Change in glycemic control predicts change in weight in adolescent boys with type 1 diabetes. <i>Pediatric Diabetes</i> , 2003, 4, 162-167.	1.2	7

#	ARTICLE	IF	CITATIONS
37	Regression of Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2003, 348, 2285-2293.	13.9	719